IXC 0.00% 7.2¢ invex therapeutics ltd

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-168

  1. 285 Posts.
    lightbulb Created with Sketch. 82
    No arguments on the asymmetric risk reward play here - IXC is now ~13% portfolio weighting for me!

    My point of looking at the sell side is try understand why the over-powering flow of selling over the past year. I'm reaching a similar conclusion as you - it's mainly early-stage investors responsible for the selling. For these investors, they already made a sizeable return from IXC and thus were happy to sell. It's not a reflection of IXC's future prospects, which are solid and should see the share price rise in multiples from today's levels.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.000(0.00%)
Mkt cap ! $5.411M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
3 158 7.4¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 5000 1
View Market Depth
Last trade - 16.12pm 29/07/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.